Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. The electro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ming, Chen, Jiayi, Yuan, Yanyan, Zou, Zuquan, Lai, Xiaolong, Rahmani, Daud M, Wang, Fuyan, Xi, Yang, Huang, Qin, Bu, Shizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557948/
https://www.ncbi.nlm.nih.gov/pubmed/28811622
http://dx.doi.org/10.1038/s41598-017-07921-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557948/
https://www.ncbi.nlm.nih.gov/pubmed/28811622
http://dx.doi.org/10.1038/s41598-017-07921-2

Ejemplares similares